文献速递冠心病心力衰竭与心肌病

微轴流泵对梗死相关心源性休克的血液动力学与代谢影响:DanGer Shock 随机临床试验亚组研究

Microaxial Flow Pump Hemodynamic and Metabolic Effects in Infarct-Related Cardiogenic Shock: A Substudy of the DanGer Shock Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2025-01-01

该研究为 DanGer Shock 试验亚组分析,纳入 324 例接受 ICU 治疗的 STEMI 合并心源性休克患者,比较微轴流泵(MAFP)联合标准治疗与单纯标准治疗。结果显示 MAFP 组在维持平均动脉压高于 65 mmHg 目标的同时,血管活性药物使用更少,乳酸水平更低且更快恢复正常。

要点

  • MAFP 组在维持血流动力学稳定的同时减少血管升压药和正性肌力药使用。
  • MAFP 组到达 ICU 时动脉乳酸较标准治疗组平均低 1.3 mmol/L(95%CI 0.7-1.9)。
  • MAFP 组乳酸恢复正常(<2 mmol/L)较标准治疗组提前 12 小时(95%CI 5-18)。

核心结论

  • 在 STEMI 合并心源性休克患者中,使用 MAFP 可减少血管升压药和正性肌力药用量,同时维持血流动力学稳定并更快实现乳酸正常化。

研究设计与样本

  • DanGer Shock 试验为国际、多中心、开放标签随机临床试验,本亚组分析纳入 324 例接受 ICU 治疗的患者。
  • 患者来自丹麦、德国和英国的 14 个心脏中心,MAFP 组 169 例(52%),标准治疗组 155 例(48%)。
  • 纳入标准包括 STEMI 且收缩压低于 100 mmHg 或正在使用血管升压药、左心室射血分数低于 45%、动脉乳酸大于 2.5 mmol/L。
  • 排除心脏骤停后昏迷、机械并发症或右心室衰竭患者,以及导管室或 ICU 入住时死亡者。

主要发现

  • 两组心率无差异,平均动脉压均高于 65 mmHg 治疗目标,但 MAFP 组血管活性-正性肌力评分(VIS)更低。
  • 随机化时两组动脉乳酸无差异,但到达 ICU 时 MAFP 组乳酸显著更低(平均差 1.3 mmol/L;95%CI 0.7-1.9 mmol/L),差异持续至观察前 24 小时。
  • MAFP 组乳酸恢复正常(<2 mmol/L)较标准治疗组提前 12 小时(95%CI 5-18 小时)。

临床怎么用

  • 对于 STEMI 合并心源性休克且符合入选标准的患者,可考虑使用 MAFP 以降低血管活性药物需求并促进乳酸清除。
  • 治疗中应监测平均动脉压不低于 65 mmHg 目标,并动态评估乳酸水平及血管活性-正性肌力评分。

局限性

  • 本研究为 DanGer Shock 试验的亚组分析,排除了心脏骤停后昏迷、机械并发症或右心室衰竭患者,以及导管室或 ICU 入住时死亡者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Mechanical circulatory support with a microaxial flow pump (MAFP) has been shown to improve survival in ST-elevation myocardial infarction-induced cardiogenic shock (STEMI-CS). Understanding the impact on hemodynamic stability over time is crucial for optimizing patient treatment. OBJECTIVE: To determine if an MAFP reduces the need for pharmacological circulatory support without compromising hemodynamics compared with standard care in STEMI-CS. DESIGN, SETTING, AND PARTICIPANTS: This was a substudy of the Danish-German (DanGer) Shock trial, an international, multicenter, open-label randomized clinical trial. Patients from 14 heart centers across Denmark, Germany, and the UK were enrolled. Inclusion criteria for the trial were STEMI and systolic blood pressure less than 100 mm Hg or ongoing vasopressor treatment, left ventricular ejection fraction less than 45%, and arterial lactate level greater than 2.5 mmol/L. Of the enrolled patients, after exclusions from death in the catheterization laboratory or immediately on intensive care unit (ICU) admission, the remaining patients had serial recordings of hemodynamics, arterial lactate, and use of vasoactive drugs. Patients who were in comas after cardiac arrest and patients with mechanical complications or right ventricular failure were excluded. Data were analyzed from May to September 2024. INTERVENTIONS: MAFP and standard of care or standard of care alone. MAIN OUTCOMES AND MEASURES: Hemodynamic status in terms of heart rate and blood pressure, metabolic status in terms of arterial lactate concentration, and vasoactive-inotropic score (VIS). The clinical events during the first 72 hours were as follows: death from all causes, escalation of mechanical circulatory support, and discharge alive from the ICU. RESULTS: From 355 enrolled patients, 324 (mean [IQR] age, 68 [58-75] years; 259 male [80%]) underwent ICU treatment (169 [52%] in the MAFP group, 155 [48%] in the standard-care group). Baseline characteristics were balanced. There was no difference in heart rate between groups, and mean arterial pressure was above the treatment target of 65 mm Hg in both groups but was achieved with a lower VIS in the MAFP group. No difference in arterial lactate level was found between groups at randomization, but on arrival to the ICU, the MAFP group had significantly lower arterial lactate levels compared with the standard-care group (mean difference, 1.3 mmol/L; 95% CI, 0.7-1.9 mmol/L), a difference that persisted throughout the first 24 hours of observation. The MAFP group achieved lactate normalization (<2 mmol/L) 12 hours (95% CI, 5-18 hours) before the standard-care group. CONCLUSIONS AND RELEVANCE: Use of a MAFP reduces the use of vasopressors and inotropic medication while maintaining hemodynamic stability and achieving faster normalization of lactate level in patients with STEMI-CS. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01633502.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Udesen, Beske, Hassager, et al. Microaxial Flow Pump Hemodynamic and Metabolic Effects in Infarct-Related Cardiogenic Shock: A Substudy of the DanGer Shock Randomized Clinical Trial. JAMA Cardiol. 2025. PMID: 39462240. doi:10.1001/jamacardio.2024.4197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。